<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382483</url>
  </required_header>
  <id_info>
    <org_study_id>16EXO401</org_study_id>
    <secondary_id>17EXO402</secondary_id>
    <secondary_id>17EXO403</secondary_id>
    <nct_id>NCT03382483</nct_id>
  </id_info>
  <brief_title>Observational, Non-interventional Use of LIPUS to Mitigate Fracture Non-union in Patients at Risk</brief_title>
  <acronym>BONES</acronym>
  <official_title>A Prospective, Patient-centric, Observational, Consecutive Enrollment, Non-interventional Study of Patients At Risk for Fracture Non-union Treated With EXOGEN Compared to a National Healthcare Claims Database Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioventus LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is one of three separate studies of the Bioventus Observational Non-interventional&#xD;
      EXOGEN Studies (BONES) program. Eligibility for each study is determined by fractured bone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective arm of this non-interventional, observational study is designed to collect&#xD;
      real world evidence from patients at risk of a fracture non-union across the US receiving&#xD;
      EXOGEN treatment. Patients will be followed for 9 months post fracture. As a&#xD;
      non-interventional study, the treating clinician will continue to provide routine care&#xD;
      without research intervention or dictation by a protocol. A medically staffed&#xD;
      Direct-to-Patient Contact Center will serve as a central investigational site with scheduled&#xD;
      and structured direct-to-patient contacts via phone/email/text/web based surveys to obtain&#xD;
      informed consent and collect data directly from the patient. For all prospective patients,&#xD;
      primary effectiveness data will be obtained directly from the medical records of the treating&#xD;
      physician.&#xD;
&#xD;
      The comparator arm of this study will be a retrospective cohort of patients within a national&#xD;
      health insurance claims database. An extract of this database will be taken and eligible&#xD;
      controls derived via propensity score analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">May 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adjunctive treatment with low intensity pulsed ultrasound therapy mitigates the risk of fracture non-union in patients at risk</measure>
    <time_frame>9 month</time_frame>
    <description>To compare incidence of fracture non-union in patients utilizing the EXOGEN device with patients receiving standard of care alone</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">12387</enrollment>
  <condition>Mitigation of Fracture Non-union in Patients at Risk</condition>
  <arm_group>
    <arm_group_label>EXOGEN Treated</arm_group_label>
    <description>Patients prescribed EXOGEN and treatment initiated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-EXOGEN Treated</arm_group_label>
    <description>Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low intensity pulsed ultrasound</intervention_name>
    <description>bone growth stimulator</description>
    <arm_group_label>EXOGEN Treated</arm_group_label>
    <other_name>EXOGEN</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective EXOGEN Treated Patients: Adult patients (21-80 years old) in the United States&#xD;
        (US) at risk for the development of fracture non-union who have been prescribed EXOGEN as&#xD;
        adjunctive treatment for a specific bone fracture.&#xD;
&#xD;
        Retrospective Non-EXOGEN Treated Claims Data Cohort: Adult patients (21-80 years old) in&#xD;
        the US at risk for development of fracture non-union who are covered under commercial&#xD;
        insurance within the MarketScan database for 18 contiguous months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be willing to provide voluntary informed consent&#xD;
&#xD;
          2. Male or female age 21-80 on fracture date&#xD;
&#xD;
          3. Must be willing to sign for release of medical insurance claim billing records from&#xD;
             the treating clinician, pertaining to the fracture and fracture treatment&#xD;
&#xD;
          4. Fluency in English and/or Spanish&#xD;
&#xD;
          5. Prescriptive initiation of therapy with the EXOGEN Ultrasound Bone Healing System&#xD;
             (Model number 71034400) for a specified fracture&#xD;
&#xD;
          6. Bone specific fracture&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient report of treatment with an electrical bone growth stimulation device (e.g.,&#xD;
             pulsed electromagnetic field (PEMF) or capacitive coupling (CC) based devices) for&#xD;
             bone fracture in 9-months pre-index period up to baseline phone contact&#xD;
&#xD;
          2. Pregnant on fracture index date&#xD;
&#xD;
          3. Evidence that prescription for EXOGEN has been written to treat a fracture non-union&#xD;
             or mal-union (i.e, ICD-10-CM code with seventh character modifier of K, P or S).&#xD;
&#xD;
          4. Evidence that prescription for EXOGEN has been written to treat a pathologic fracture&#xD;
             (ICD-10-CM code M80. or M84.) or neuropathic bone (ICD-10-CM code M14.6)&#xD;
&#xD;
          5. Patient with a concurrent fracture of the other bones of interest&#xD;
&#xD;
          6. Patients who are or anticipate living or receiving fracture treatment outside of the&#xD;
             US during the post-index fracture period&#xD;
&#xD;
          7. Patient report of history of primary or metastatic bone cancer&#xD;
&#xD;
          8. Patient report of bone infection or osteomyelitis of index fracture at baseline&#xD;
             contact&#xD;
&#xD;
          9. Patient report of prior bone specific fracture in 9-months pre-index period&#xD;
&#xD;
         10. Patient prescribed EXOGEN as part of a Worker Compensation claim&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSU Head of Orthopedics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christina Mack, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>IQUVIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CliniCallRN</name>
      <address>
        <city>Jericho</city>
        <state>New York</state>
        <zip>11753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Ununited</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

